Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association of TNF-α-308 and -238 Polymorphisms with Risk of Cervical Cancer: A Meta-analysis

  • Pan, Feng (Department of Oncology, Anhui Provincial Hospital affiliated to Anhui Medical University) ;
  • Tian, Jing (Menzies Research Institute, University of Tasmania) ;
  • Ji, Chu-Shu (Department of Oncology, Anhui Provincial Hospital affiliated to Anhui Medical University) ;
  • He, Yi-Fu (Department of Oncology, Anhui Provincial Hospital affiliated to Anhui Medical University) ;
  • Han, Xing-Hua (Department of Oncology, Anhui Provincial Hospital affiliated to Anhui Medical University) ;
  • Wang, Yong (Department of Oncology, Anhui Provincial Hospital affiliated to Anhui Medical University) ;
  • Du, Jian-Ping (Department of Oncology, Anhui Provincial Hospital affiliated to Anhui Medical University) ;
  • Jiang, Feng-Shou (Department of Oncology, Anhui Provincial Hospital affiliated to Anhui Medical University) ;
  • Zhang, Ying (Department of Geriatrics, the Third Affiliated Hospital of Anhui Medical University) ;
  • Pan, Yue-Yin (Department of Oncology, the First Affiliated Hospital of Anhui Medical University Hefei) ;
  • Hu, Bing (Department of Oncology, Anhui Provincial Hospital affiliated to Anhui Medical University)
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Published data on the associations between tumor necrosis factor-alpha (TNF-${\alpha}$) promoter -308G>A and -238G>A polymorphisms and cervical cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Data were collected from MEDLINE and PubMed databases. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated in a fixed/random effect model. 13 separate studies including 3294 cases and 3468 controls were involved in the meta-analysis. We found no association between TNF-${\alpha}$-308G>A polymorphism and cervical cancer in overall population. In subgroup analysis, significantly elevated risks were found in Caucasian population (A vs. G: OR = 1.43, 95% CI = 1.00-2.03; AA vs. GG: OR = 2.09, 95% CI = 1.34-3.25; Recessive model: OR = 2.09, 95% CI = 1.35-3.25) and African population (GA vs. GG: OR = 1.53, 95% CI = 1.02-2.30). An association of TNF-${\alpha}$-238G>A polymorphism with cervical cancer was found (A vs. G: OR = 0.61, 95% CI = 0.47-0.78; GA vs. GG: OR = 0.59, 95% CI = 0.45-0.77; Dominant model: OR = 0.59, 95% CI = 0.46-0.77). When stratified by ethnicity, similar association was observed in Caucasian population (A vs. G: OR = 0.62, 95% CI = 0.46-0.84; GA vs. GG: OR = 0.59, 95% CI = 0.43-0.82; Dominant model: OR = 0.60, 95% CI = 0.44-0.83). In summary, this meta-analysis suggests that TNF-${\alpha}$-238A allele significantly decreased the cervical cancer risk, and the TNF-${\alpha}$-308G>A polymorphism is associated with the susceptibility to cervical cancer in Caucasian and African population.

Keywords

References

  1. Abrahamsson J, Carlsson B, Mellander L (1993). Tumor necrosis factor-alpha in malignant disease. Am J Pediatr Hematol Oncol, 15, 364-9.
  2. Bazzoni F, Beutler B (1996). The tumor necrosis factor ligand and receptor families. N Engl J Med, 334, 1717-25. https://doi.org/10.1056/NEJM199606273342607
  3. Beutler B, Bazzoni F (1998). TNF, apoptosis and autoimmunity: a common thread? Blood Cells Mol Dis, 24, 216-30. https://doi.org/10.1006/bcmd.1998.0187
  4. Calhoun ES, McGovern RM, Janney CA, et al (2002). Host genetic polymorphism analysis in cervical cancer. Clin Chem, 48, 1218-24.
  5. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29. https://doi.org/10.2307/3001666
  6. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7. https://doi.org/10.1038/nature01322
  7. D'Alfonso S, Richiardi PM (1994). A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics, 39, 150-4.
  8. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  9. Deshpande A, Nolan JP, White PS, et al (2005). TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis, 191, 969-76. https://doi.org/10.1086/427826
  10. Dranoff G (2004). Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer, 4, 11-22. https://doi.org/10.1038/nrc1252
  11. Duarte I, Santos A, Sousa H, et al (2005). G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun, 334, 588-92. https://doi.org/10.1016/j.bbrc.2005.06.137
  12. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  13. Fong CL, Siddiqui AH, Mark DF (1994). Identification and characterization of a novel repressor site in the human tumor necrosis factor alpha gene. Nucleic Acids Res, 22, 1108-14. https://doi.org/10.1093/nar/22.6.1108
  14. Gostout BS, Poland GA, Calhoun ES, et al (2003). TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol, 88, 326-32. https://doi.org/10.1016/S0090-8258(02)00074-4
  15. Govan VA, Constant D, Hoffman M, et al (2006). The allelic distribution of -308 Tumor Necrosis Factor-alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer, 6, 24. https://doi.org/10.1186/1471-2407-6-24
  16. Hajeer AH, Hutchinson IV (2000). TNF-alpha gene polymorphism: clinical and biological implications. Microsc Res Tech, 50, 216-28. https://doi.org/10.1002/1097-0029(20000801)50:3<216::AID-JEMT5>3.0.CO;2-Q
  17. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  18. Ivansson EL, Juko-Pecirep I, Gyllensten UB (2010). Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol, 116, 544-8. https://doi.org/10.1016/j.ygyno.2009.10.084
  19. Ivansson EL, Magnusson JJ, Magnusson PK, et al (2008). MHC loci affecting cervical cancer risk: distinguishing the effects of HLA-DQB1 and non-HLA genes TNF, LTA, TAP1 and TAP2. Genes Immun, 9, 613-23. https://doi.org/10.1038/gene.2008.58
  20. Jang WH, Yang YI, Yea SS, et al (2001). The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett, 166, 41-6. https://doi.org/10.1016/S0304-3835(01)00438-4
  21. Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  22. Kaluza W, Reuss E, Grossmann S, et al (2000). Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol, 114, 1180-3. https://doi.org/10.1046/j.1523-1747.2000.00001.x
  23. Kohaar I, Thakur N, Salhan S, et al (2007). TNFalpha-308G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol, 29, 249-56.
  24. Kroeger KM, Carville KS, Abraham LJ (1997). The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol, 34, 391-9. https://doi.org/10.1016/S0161-5890(97)00052-7
  25. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  26. Moore RJ, Owens DM, Stamp G, et al (1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med, 5, 828-31. https://doi.org/10.1038/10552
  27. Nakashima J, Tachibana M, Ueno M, et al (1998). Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res, 4, 1743-8.
  28. Pooja S, Francis A, Bid HK, et al (2011). Role of ethnic variations in TNF-${\alpha}$ and TNF-${\beta}$ polymorphisms and risk of breast cancer in India. Breast Cancer Res Treat, 126, 739-47. https://doi.org/10.1007/s10549-010-1175-6
  29. Shih CM, Lee YL, Chiou HL, et al (2006). Association of TNFalpha polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer, 52, 15-20. https://doi.org/10.1016/j.lungcan.2005.11.011
  30. Shishodia S, Majumdar S, Banerjee S, et al (2003). Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with downregulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res, 63, 4375-83.
  31. Singh H, Jain M, Sachan R, et al (2009). Association of TNFA (-308G>A) and IL-10 (-819C>T) promoter polymorphisms with risk of cervical cancer. Int J Gynecol Cancer, 19, 1190-4. https://doi.org/10.1111/IGC.0b013e3181a3a3af
  32. Sousa H, Breda E, Santos AM, et al (2011). Genetic risk markers for nasopharyngeal carcinoma in Portugal: tumor necrosis factor alpha -308G >A polymorphism. DNA Cell Biol, 30, 99-103. https://doi.org/10.1089/dna.2010.1086
  33. Stanczuk GA, Sibanda EN, Tswana SA, et al (2003). Polymorphism at the -308-promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer, 13, 148-53. https://doi.org/10.1046/j.1525-1438.2003.13046.x
  34. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  35. Wang Q, Zhang C, Walayat S, et al (2011). Association between cytokine gene polymorphisms and cervical cancer in a Chinese population. Eur J Obstet Gynecol Reprod Biol, 158, 330-3. https://doi.org/10.1016/j.ejogrb.2011.05.019
  36. Wang SS, Bratti MC, Rodriguez AC, et al (2009). Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis, 199, 20-30. https://doi.org/10.1086/595563
  37. zur Hausen H (2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer, 2, 342-50. https://doi.org/10.1038/nrc798

Cited by

  1. Role of Cytokines in Genesis, Progression and Prognosis of Cervical Cancer vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3851
  2. TNF-α −308 G/A as a Risk Marker of Cervical Cancer Progression in the Polish Population vol.19, pp.1, 2015, https://doi.org/10.1007/s40291-015-0130-y
  3. Tumor Necrosis Factor Alpha (−238 / −308) and TNFRII-VNTR (−322) Polymorphisms as Genetic Biomarkers of Susceptibility to Develop Cervical Cancer Among Tunisians vol.21, pp.2, 2015, https://doi.org/10.1007/s12253-014-9826-2
  4. Association of Single Nucleotide Polymorphisms in Tumor Necrosis Factor-Alpha with Cervical Cancer Susceptibility vol.71, pp.1, 2015, https://doi.org/10.1007/s12013-014-0165-4
  5. Risk allelic load in Th2 and Th3 cytokines genes as biomarker of susceptibility to HPV-16 positive cervical cancer: a case control study vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2364-4
  6. Lack of Associations between TNF-α Polymorphisms and Cervical Cancer in Thai women vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.953
  7. State of Art of Cancer Pharmacogenomics in Latin American Populations vol.18, pp.6, 2017, https://doi.org/10.3390/ijms18060639
  8. -308 G/A and IL-8 -251 T/A Genes Associated with Urothelial Carcinoma: A Case-Control Study vol.2018, pp.2314-6141, 2018, https://doi.org/10.1155/2018/3148137
  9. Association of 42 SNPs with genetic risk for cervical cancer: an extensive meta-analysis vol.16, pp.1, 2015, https://doi.org/10.1186/s12881-015-0168-z